Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump committed ‘repeated’ fraud by inflating real estate value, New York judge rules
    • ‘As bad as it gets’: Donald Trump’s New York business empire imperilled by fraud ruling
    • German far-right party surges on immigrant ‘dystopia’
    • Chinese TV presenter linked to missing foreign minister had surrogate child in US
    • Azerbaijan arrests Russian-Armenian billionaire fleeing Nagorno-Karabakh
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • Scrapping UK inheritance tax hands £1mn to richest 1%, finds IFS
    • Labour says it will not strip private schools of charitable status
    • ‘I am Marmite’: Tory mayoral hopeful tries to win over Londoners
    • UK home sellers increase discounts to secure deals, Zoopla data shows
    • Farming subsidies trigger row over future of British countryside
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Jailed oligarch accuses TPG of colluding with Kremlin to seize $14bn assets
    • McKinsey pays out another $230mn to settle opioid cases
    • Meta pays £149mn to break London office lease
    • GB News suspends Dan Wootton after Laurence Fox comments
    • PwC Australia’s culture attacked in tax leak scandal report
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • UK regulator to launch review of private market valuations
    • News updates from September 27: Soldier Travis King ‘in US custody’, Argentina’s poverty rate hits 40%
    • Fed’s ‘higher for longer’ message hits US stocks and bonds
    • Crude climbs above $96 a barrel on US stockpiles concern
    • Live news: Nagorno-Karabakh republic to cease to exist
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Rishi Sunak’s new strategy exposes 13 years of Tory failure
    • How China can avoid the Japan trap
    • What the world should expect from a second Trump term
    • Francis Drake’s swashbuckling spirit lives on in Kyiv’s Black Sea battles
    • A power grab against private equity threatens the US economy
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
    • Success is more complicated than one exceptional individual
    • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
    • What Burberry taught me about the marketed mind
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Why Linda Yaccarino took on the wildest job in Silicon Valley
    • Horizon 22 trumps the Shard to become London’s highest viewpoint (and it’s free)
    • On the ranch with Ralph Lauren
    • Booker Prize 2023: the shortlisted titles reviewed
    • Biden, Feinstein and the ageing of US politics
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Eisai Co Ltd

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Thursday, 6 July, 2023
    Dementia
    US regulators approve first drug to slow progression of Alzheimer’s

    Move by Food and Drug Administration paves way for millions of Americans to access medicine

    Vials and packaging for the medication Leqembi
  • Saturday, 17 June, 2023
    Pharmaceuticals sector
    Drugmaker warns US data rules threaten access to Alzheimer’s treatment

    Japan’s Eisai says it will not finalise Leqembi spending plans until government clarifies financial support

    Brain scans from a patient suffering from Alzheimer’s disease
  • Monday, 8 May, 2023
    Dementia
    Two Alzheimer’s drugs offer hope to patients after decades of waiting

    In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

    Computer scan of a brain
  • Wednesday, 11 January, 2023
    Anjana Ahuja
    New Alzheimer’s drug straddles uneasy gulf between help and harm

    For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

    Illustration of a man falling into darkness (to represent Alzheimer’s) and the rope coming down from the light is a spiky vine to suggest the ‘help’ can still cause harm
  • Friday, 6 January, 2023
    Pharmaceuticals sector
    US approves Alzheimer’s drug that slows rate of cognitive decline

    High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially

    Leqembi package and vial
  • Friday, 2 December, 2022
    Pharmaceuticals sector
    Swedish scientist behind Alzheimer’s drug has big ambitions

    Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

    Lars Lannfelt, inventor of the ground-breaking drug lecanemab
  • Friday, 2 December, 2022
    The editorial board
    A glimmer of hope in treating Alzheimer’s disease

    Dementia drug development, diagnostics and delivery still require much more investment

    A series of brightly coloured scans of brain activity
  • Wednesday, 30 November, 2022
    Dementia
    Eisai says Alzheimer’s drug did not cause deaths of trial patients

    Japanese company refuses to rule out possibility treatment contributed to brain bleeds

  • Tuesday, 29 November, 2022
    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Shares fall 11% following two patient deaths in trials of lecanemab

    Haruo Naito, the 74-year-old chief executive of Japan’s Eisai
  • Monday, 28 November, 2022
    LexDrugs research
    Dementia/Biogen: causal controversy means investors must take a stance Premium content

    The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

  • Wednesday, 28 September, 2022
    Pharmaceuticals sector
    Biogen and Eisai shares surge after Alzheimer’s drug trial success

    Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

    A scan of a brain affected by Alzheimer’s disease
  • Thursday, 21 July, 2022
    ESG investing
    Drugmaker Eisai secures ESG money by linking investments to value

    ‘Hard numbers’ model designed by ex-head of finance is winning followers among leading investors and corporate Japan

    Ryohei Yanagi stands by a wooden wall. On his right is a plant. His right hand is in his right pocket, while his left hand rests on a waist-high divider
  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Wednesday, 16 June, 2021
    Pharmaceuticals sector
    Biogen’s Japanese partner calls for global action on Alzheimer’s

    Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

    A researcher works on the development of the medication aducanumab in Cambridge
  • Friday, 22 March, 2019
    Drugs research
    What next for Alzheimer’s research after latest drug failure?

    Biogen’s aducanumab was last hope of one approach to the disease, but there are others

    This March 23, 2017 photo provided by the Sunnybrook Health Sciences Centre shows brain scans of patient Rick Karr as staff members treat him at the facility in Toronto, Canada. Karr was the first Alzheimer's patient treated with focused ultrasound to open the blood-brain barrier. Scientists are using ultrasound waves to temporarily jiggle an opening in the brain’s protective shield, in hopes the technique one day might help drugs for Alzheimer’s, brain tumors and other diseases better reach their target. (Kevin Van Paassen/Sunnybrook Health Sciences Centre via AP)
  • Thursday, 21 March, 2019
    Drugs research
    Biogen shares slump on Alzheimer’s drug trial failure

    Drugmaker loses $18bn from market value after deciding to discontinue trials

    The disappointment adds aducanumab to the list of once-promising Alzheimer’s drugs that have failed in the late stages of testing
  • Wednesday, 28 November, 2018
    Brexit
    Japanese ambassador to UK calls for pragmatism on Brexit talks
    epa06506083 Japanese Ambassador to the United Kingdom Koji Tsuruoka arrives at 10 Downing Street for a meeting with British Prime Minister Theresa May in London, Britain, 08 February 2018. British Prime Theresa May held a round table meeting with Japanese investors at 10 Downing Street in London EPA/ANDY RAIN
  • Monday, 19 November, 2018
    Brexit
    Pharma ignores the squabbling and prepares for a hard Brexit

    Costs are irrecoverable in industry that has to plan for all possible scenarios

    Eisai Europe, Hatfield. Picture shows Alex Felthouse, MD Eisai Manufacturing PHOTOGRAPH BY DANIEL JONES 2018 07815 853503 info@danieljonesphotography.co.uk www.danieljonesphotography.co.uk
  • Wednesday, 25 July, 2018
    Pharmaceuticals sector
    Biogen, Eisai Alzheimer’s drug slowed patients’ cognitive decline
  • Thursday, 5 July, 2018
    Pharmaceuticals sector
    Biogen, Eisai say Alzheimer’s drug succeeds in mid-stage trial
  • Thursday, 8 March, 2018
    LexPharmaceuticals sector
    Eisai/Merck: doubling up, and down Premium content

    Japanese group’s tie-up with US pharma on cancer drug will boost its research on Alzheimer’s

    cancer cell made in 3d software
  • Thursday, 15 January, 2015
    The Big Read
    Healthcare: Counting the cost of cancer

    The cost of new drugs is pushing health budgets to the limit

    ^BCancer cell division.^b Coloured scanning electron micrograph (SEM) of two prostate cancer cells in the final stage of cell division (cytokinesis). During this stage the cells' cytoplasm divides. Here the cells are joined by a thin cytoplasmic bridge. Cancer cells divide rapidly in a chaotic, uncontrolled manner. They may clump to form tumours, which invade and destroy surrounding tissues. Prostate cancer affects the prostate gland of the male reproductive system, located below the bladder. It can cause difficulty in passing urine and an increased need to urinate. Magnification unknown.
  • Sunday, 11 January, 2015
    UK companies
    Drug companies call for overhaul of NHS cost-benefit evaluations

    Health service poised to stop paying for expensivecostly cancer therapies

  • Wednesday, 7 January, 2015
    Pharmaceuticals sector
    Drugmakers threaten NHS with lawsuits over cancer ruling

    Health service expected to stop paying for some expensive treatments

    Breast Cancer Tissue, Color Enhanced Micrograph
  • Monday, 27 May, 2013
    Pharmaceuticals sector
    Japan in pioneering partnership to fund global health research
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today’s Newspaper (FT Digital Edition)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In